VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DSGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DSGNDesign Therapeutics, Inc.
$9.47$591M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksDSGNFinancials

Design Therapeutics, Inc. (DSGN) Income Statement

7Y historyFree accessUpdated daily

Revenue remained absent across all ten quarters, with R&D consuming roughly 75% to 80% of operating expenses and stock compensation of $3.1M to $4.1M per quarter partially cushioning the reported operating loss.

Income StatementBalance SheetCash FlowRatios

DSGN Income Statement

Annual statement

DSGN Income Statement

Design Therapeutics, Inc. (DSGN) annual income statement — 7-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Sales/Revenue0000000834
Revenue Growth %-------100%-
Cost of Goods Sold000537K466K05K1.65K
COGS % of Revenue-------198.32%
Gross Profit000-537K-466K0-5K-820
Gross Margin %--------98.32%
Gross Profit Growth %--100%-15.24%-100%-509.76%-
Operating Expenses82.28M79.47M62.38M77.65M67.13M35.83M8.55M1.91M
OpEx % of Revenue-------228776.98%
Selling, General & Admin21.16M20.34M18.03M21.13M18.98M11.05M2.5M1.09M
SG&A % of Revenue-------130455.64%
Research & Development61.12M59.13M44.35M57.06M48.61M24.78M6.06M1.65M
R&D % of Revenue-------198321.34%
Other Operating Expenses000-537K-466K00-834K
Operating Income-82.28M-79.47M-62.38M-78.19M-67.59M-35.83M-8.56M-1.91M
Operating Margin %--------228776.98%
Operating Income Growth %--27.39%20.22%-15.68%-88.64%-318.78%-348.43%-
EBITDA-81.68M-78.84M-61.79M-77.65M-67.19M-35.7M-8.55M0
EBITDA Margin %--------
EBITDA Growth %-5.56%-27.61%20.43%-15.58%-88.19%-317.52%--
D&A (Non-Cash Add-back)600K622K596K537K406K129K5K1.91M
EBIT-78.04M-69.79M-49.59M-66.86M-63.31M-35.53M-8.28M-2.05M
Net Interest Income8.2M9.68M12.79M00000
Interest Income8.2M9.68M12.79M00000
Interest Expense00000000
Other Income/Expense8.2M9.68M12.79M11.33M4.29M298K276K-139K
Pretax Income-74.09M-69.79M-49.59M-66.86M-63.31M-35.53M-8.28M-2.05M
Pretax Margin %--------245443.65%
Income Tax00000000
Effective Tax Rate %0%0%0%0%0%0%0%0%
Net Income-74.09M-69.79M-49.59M-66.86M-63.31M-35.53M-8.28M-2.05M
Net Margin %--------245443.65%
Net Income Growth %-9.84%-40.74%25.84%-5.61%-78.17%-329.14%-304.49%-
Net Income (Continuing)-74.09M-69.79M-49.59M-66.86M-63.31M-35.53M-8.28M-2.05M
Discontinued Operations00000000
Minority Interest00000000
EPS (Diluted)-1.18-1.22-0.88-1.19-1.14-0.77-0.30-0.08
EPS Growth %-0.84%-38.64%26.05%-4.39%-48.05%-156.67%-298.41%-
EPS (Basic)--1.22-0.88-1.19-1.14-0.77-0.30-0.08
Diluted Shares Outstanding63.04M57.33M56.59M55.98M55.71M45.94M27.19M27.19M
Basic Shares Outstanding63.04M57.33M56.59M55.98M55.71M45.94M27.19M27.19M
Dividend Payout Ratio--------

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Limited cash runway

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Pre-Revenue Profile Persists Through Ten Quarters

According to the reported income statement, DSGN has recorded no revenue across the ten quarters shown, with the only top-line activity being a $151.0K COGS entry in 2024Q2 that produced a negative gross profit, leaving growth metrics without a meaningful base.

Because revenue is absent throughout the series, year-over-year growth rates cannot be meaningfully interpreted, and the reported quarterly swings in loss per share reflect expense timing rather than commercial momentum. The lone COGS line in 2024Q2 likely relates to clinical or pre-commercial materials rather than product sales, which suggests investors should not read it as an early revenue signal. Growth durability therefore hinges entirely on future clinical milestones, not on any observable income trend.

R&D Drives Losses Despite Modest Overhead

R&D expense rose from $10.4M in 2024Q2 to $16.9M in 2026Q3, while SG&A stayed in a narrow $4.4M to $5.8M band, indicating that research spend, not overhead, is the dominant driver of the operating loss.

The operating loss widened from $15.0M to $22.2M over this period, and nearly all of that deterioration tracks R&D growth, which suggests the cost base is scaling with clinical activity rather than with administrative build-out. SG&A appears comparatively stable, implying reasonable overhead discipline. Operating leverage is effectively negative, since expenses are rising without any offsetting revenue to absorb them.

Stock Compensation Cushions Reported Cash Strain

SBC ran between $3.1M and $4.1M per quarter, roughly 15% to 20% of the reported operating loss, which means a meaningful share of the expense base is non-cash and flatters the cash burn picture.

Net loss figures are therefore somewhat overstated relative to cash consumption, and analysts should adjust for SBC when estimating runway. The 2026Q3 EPS of -0.32 beat the cited consensus of -0.39, but a single quarter's per-share figure does not establish sustainable expense control. Non-operating items appear minimal given that net loss tracks closely with operating loss.

Clinical Spend Dominates the Cost Structure

Based on the reported figures, R&D accounts for roughly 75% to 80% of total operating expenses in recent quarters, making clinical program timing the single most important determinant of quarterly burn.

Given that R&D rose by about $6.5M across the observed period while SG&A moved only marginally, expense management appears concentrated in administrative areas already held relatively flat. The cost base is largely non-discretionary while trials are active, which limits management's ability to quickly reduce burn without program delays. Investors should monitor whether upcoming trial phases push R&D materially higher.

Runway Risk Outweighs Recent EPS Improvement

The 2026Q3 loss per share of -0.32 beat consensus, but with operating losses still near $22.2M per quarter and no revenue offset, the reported figures alone suggest a financing event may be required, warranting further investigation of liquidity.

A narrower-than-expected per-share loss may reflect favorable timing of clinical spend rather than durable cost control, and the income statement does not disclose current cash or burn rates needed to confirm runway. The reported negative ROE of -30.7% and absence of revenue suggest dependence on external equity financing, which could dilute shareholders if capital is raised at depressed valuations. Analysts should treat the EPS beat cautiously until balance sheet data confirms liquidity.

DSGN — Frequently Asked Questions

Quick answers to the most common questions about buying DSGN stock.

What was Design Therapeutics, Inc.'s (DSGN) revenue in 2025?

For fiscal year 2025, Design Therapeutics, Inc. (DSGN) reported total revenue of $0.0M. This represents a 100.0% decline compared to $0.0M in 2019.

Is Design Therapeutics, Inc. (DSGN) profitable?

Design Therapeutics, Inc. (DSGN) reported a net loss of $69.8M for the fiscal year ending 2025.